On February 23rd, Shanhe Pharmaceutical Co., Ltd. announced that its shareholder, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., plans to reduce its holdings of the company’s shares by a total of no more than 6.978 million shares, or 3% of the company’s total share capital, through centralized bidding and bulk trading due to operational needs.
Scan code to share